$PMCB PharmaCyte Biotech Big at Heart, Long in Talent, Full of Setbacks
PharmaCyte Biotech (PMCB) had a shareholder call to address the developments with their pancreatic cancer and diabetes trials. Most of the call was spent recapping the challenges that they faced in the pathway to regulatory […]